The WorldPostJuly 22, 2016
Recent memos allegedly leaked from the Colombian Embassy in
Washington describe intense pressure by the pharmaceutical industry and
its Congressional allies to discourage Colombia’s efforts to half the
local price of Novartis’ Gleevec, one of the leading medications used to
treat Chronic Myelogenous Leukemia (CML). See Huffington Post “Colombia Fears U.S. May Reject Peace Plan To Protect Pharma Profits.”
As a US citizen, as the Representative of the UN High Commissioner
for Human Rights in Colombia since 2012, and as a person with CML, I
believe that if US citizens and members of Congress know what I know
about Colombia — and about CML — they would see that these strong-arm
tactics cruelly threaten human lives, and also undermine our own
economic and security interests at a critical time for Colombia.
Click here for the ENTIRE article.
